Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 24 Sep 2026 · Editorial standards

Leucovorin is named as a drug or biological intervention in 53 clinical trials in our USA, China, UK, Ireland and India trial registers, 30 of which are recruiting. Lead sponsors include Merck Sharp & Dohme LLC (4), Astellas Pharma Global Development, Inc. (4) and Seagen, a wholly owned subsidiary of Pfizer (3). Registered phases: Phase 2, Phase 1, Phase 3, Phase 1/2, Phase 2/3 and Not applicable. Conditions studied include Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Biliary Tract Cancer.

Clinical trials of Leucovorin

53 trials

NCT ID	Study	Phase	Status	Lead sponsor	Register
NCT05253651	A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer Colorectal Neoplasms	Phase 3	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	Ireland, UK, USA, China
NCT07043400	A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (ClinicalTrials.gov ↗) Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	BeOne Medicines	UK, USA, China
NCT07409272	A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma	Phase 3	Recruiting	Astellas Pharma Global Development, Inc.	UK, USA, China
NCT07431281	Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 (ClinicalTrials.gov ↗) Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
NCT07621718	Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) (ClinicalTrials.gov ↗) Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC	Phase 3	Recruiting	Revolution Medicines, Inc.	USA
NCT03899155	Pan Tumor Rollover Study (ClinicalTrials.gov ↗) Cancer	Phase 2	Recruiting	Bristol-Myers Squibb	Ireland, UK, USA, China
NCT06219941	AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 (ClinicalTrials.gov ↗) Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer	Phase 2	Recruiting	AstraZeneca	UK, USA, China
NCT06820463	A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (ClinicalTrials.gov ↗) Metastatic Colorectal Cancer	Phase 2	Recruiting	AbbVie	UK, USA
NCT06948448	A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer (ClinicalTrials.gov ↗) Colorectal Cancer	Phase 2	Recruiting	Ono Pharmaceutical Co., Ltd.	USA
NCT07415031	A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies (ClinicalTrials.gov ↗) Solid Tumors	Phase 2	Recruiting	Mirati Therapeutics Inc.	UK, USA, China
NCT07432295	Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) (ClinicalTrials.gov ↗) Solid Tumor, Advanced Cancer, Metastatic Cancer	Phase 2	Recruiting	I-Mab Biopharma US Limited	USA, China
NCT07474727	A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer (ClinicalTrials.gov ↗) Colorectal Cancer	Phase 2	Recruiting	Multitude Therapeutics Inc.	China
NCT07554521	A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States (ClinicalTrials.gov ↗) Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma	Phase 2	Recruiting	BeOne Medicines	USA
NCT07797816	Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer (ClinicalTrials.gov ↗) Biliary Tract Cancer	Phase 2	Recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
NCT07831993	Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer (ClinicalTrials.gov ↗) Biliary Tract Cancer	Phase 2	Recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
NCT05379595	A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (ClinicalTrials.gov ↗) Advanced or Metastatic Colorectal Cancer	Phase 1/2	Recruiting	Janssen Research & Development, LLC	USA, China
NCT06428409	A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) (ClinicalTrials.gov ↗) Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China
NCT06469944	Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) (ClinicalTrials.gov ↗) Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China
NCT06741644	A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors Advanced Solid Tumors	Phase 1/2	Recruiting	CStone Pharmaceuticals	USA, China
NCT06780111	Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) (ClinicalTrials.gov ↗) Esophageal Squamous Cell Carcinoma	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China
NCT03715933	Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas (ClinicalTrials.gov ↗) Ewing Sarcoma, Colorectal Adenocarcinoma	Phase 1	Recruiting	Inhibrx Biosciences, Inc	UK, USA
NCT05067283	A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) Advanced Solid Tumors	Phase 1	Recruiting	Merck Sharp & Dohme LLC	USA, China
NCT05365581	A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer (ClinicalTrials.gov ↗) Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma	Phase 1	Recruiting	Astellas Pharma Global Development, Inc.	USA, China
NCT05382559	A Study of ASP3082 in Adults With Advanced Solid Tumors (ClinicalTrials.gov ↗) Solid Tumor	Phase 1	Recruiting	Astellas Pharma Inc	USA, China
NCT06131840	A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms	Phase 1	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	UK, USA, China
NCT06586515	MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer	Phase 1	Recruiting	Eli Lilly and Company	Ireland, USA, China
NCT06825624	ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer (ClinicalTrials.gov ↗) Metastatic Colorectal Cancer (CRC)	Phase 1	Recruiting	Hansoh BioMedical R&D Company	China
NCT07024615	A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer Pancreatic Ductal Adenocarcinoma	Phase 1	Recruiting	Astellas Pharma Global Development, Inc.	USA
NCT07277270	A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors (ClinicalTrials.gov ↗) Neoplasms	Phase 1	Recruiting	GlaxoSmithKline	USA
NCT07318805	A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors (ClinicalTrials.gov ↗) Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer	Phase 1	Recruiting	Pfizer	USA
NCT07803783	A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy (ClinicalTrials.gov ↗) Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)	Phase 3	Not yet open	MediLink Therapeutics (Suzhou) Co., Ltd.	China
NCT06662877	Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment (ClinicalTrials.gov ↗) Biliary Tract Cancer, Second Line Treatment, Chemotherapy	Phase 2/3	Not yet open	Sun Yat-sen University	China
NCT06370754	Newly Emerging Immunotherapy for Pancreatic Cancer Treatment (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase 1/2	Not yet open	Fudan University	China
NCT07678593	A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation (ClinicalTrials.gov ↗) Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation	Phase 1/2	Not yet open	Genfleet Therapeutics (Shanghai) Inc.	China
NCT04008030	A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) Metastatic Colorectal Cancer	Phase 3	Active, closed	Bristol-Myers Squibb	Ireland, UK, USA, China
NCT04607421	A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (ClinicalTrials.gov ↗) Neoplasms	Phase 3	Active, closed	Pfizer	UK, USA, India, China
NCT06625320	Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (ClinicalTrials.gov ↗) Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma	Phase 3	Active, closed	Revolution Medicines, Inc.	USA
NCT05141721	A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer (ClinicalTrials.gov ↗) Colorectal Neoplasms	Phase 2/3	Active, closed	Seattle Project Corporation	USA
NCT03505320	A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer	Phase 2	Active, closed	Astellas Pharma Global Development, Inc.	USA
NCT04430738	Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers (ClinicalTrials.gov ↗) Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma	Phase 2	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	USA
NCT05026905	A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer (ClinicalTrials.gov ↗) Phase II, Open-label, Parallel 2-arm, Multi-center	Phase 2	Active, closed	National Health Research Institutes, Taiwan	China
NCT05382442	A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer (ClinicalTrials.gov ↗) Metastatic Colorectal Cancer	Phase 2	Active, closed	Akeso	USA, China
NCT05945823	Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors (ClinicalTrials.gov ↗) Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer	Phase 2	Active, closed	Taiho Oncology, Inc.	USA
NCT06628310	A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ClinicalTrials.gov ↗) Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma	Phase 2	Active, closed	AbbVie	UK, USA, China
NCT07257575	A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma (ClinicalTrials.gov ↗) Gastric Cancer Stage III	Phase 2	Active, closed	Guangdong Provincial People's Hospital	China
NCT06771622	Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors (ClinicalTrials.gov ↗) Solid Cancer	Phase 1/2	Active, closed	FBD Biologics Limited	China
NCT03872947	A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (ClinicalTrials.gov ↗) Solid Tumor, Colorectal Cancer, Cholangiocarcinoma	Phase 1	Active, closed	Toray Industries, Inc	USA
NCT05355701	A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (ClinicalTrials.gov ↗) Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer	Phase 1	Active, closed	Pfizer	USA
NCT05647122	First in Human Study of AZD9592 in Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms	Phase 1	Active, closed	AstraZeneca	USA, China
NCT05891171	Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ClinicalTrials.gov ↗) Advanced Cancer, Advanced Malignancies, Bladder Cancer	Phase 1	Active, closed	Arcus Biosciences, Inc.	USA
NCT06328738	ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer (ClinicalTrials.gov ↗) HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors	Phase 1	Active, closed	Enliven Therapeutics	USA
NCT06607185	A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (ClinicalTrials.gov ↗) Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer	Phase 1	Active, closed	Eli Lilly and Company	USA
NCT04562558	Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia (ClinicalTrials.gov ↗) Gestational Trophoblastic Tumor, Gestational Trophoblastic Neoplasia, Stage I Gestational Trophoblastic Tumor	Not applicable	Active, closed	xiang yang	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied

81 conditions

Condition (as registered)	Trials
Pancreatic Ductal Adenocarcinoma	7
Colorectal Cancer	7
Biliary Tract Cancer	5
Colorectal Neoplasms	4
Gastric Cancer	4
Pancreatic Cancer	4
Metastatic Colorectal Cancer	3
Gastroesophageal Junction Adenocarcinoma	3
Esophageal Adenocarcinoma	3
Solid Tumor	3
Non-small Cell Lung Cancer	2
Neoplasms	2
Metastatic Pancreatic Cancer	2
Esophageal Cancer	2
Advanced Solid Tumors	2
Gastric Adenocarcinoma	2
PDAC	2
PDAC - Pancreatic Ductal Adenocarcinoma	2
Esophageal Squamous Cell Carcinoma	2
Bladder Cancer	2
Advanced Cancer	2
Cancer	1
Carcinoma, Non-Small-Cell Lung	1
Stomach Neoplasms	1
Gastroesophageal Junction Cancer	1
Metastatic Pancreatic Adenocarcinoma	1
Ewing Sarcoma	1
Colorectal Adenocarcinoma	1
Metastatic Gastric Adenocarcinoma	1
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma	1
Solid Tumors	1
Pharmacokinetics of Zolbetuximab	1
Gastro-esophageal Junction (GEJ) Cancer	1
Pharmacokinetics of Oxaliplatin	1
HER2-positive Breast Cancer	1
HER2-positive Gastric Cancer	1
HER2 Positive Solid Tumors	1
HER2 Amplification	1
Gastroesophageal Junction (GEJ) Adenocarcinoma	1
Pancreatic Adenocarcinoma	1

+ 41 more conditions in the trial records above.

Trials by country register

Register	Leucovorin trials
Clinical trials in USA	41
Clinical trials in China	35
Clinical trials in UK	14
Clinical trials in Ireland	4
Clinical trials in India	2

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Leucovorin works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Leucovorin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Leucovorin

Clinical trials of Leucovorin

Conditions studied

Sponsors

Trials by country register

How this page is built